VF
NBIX icon

Virtu Financial’s Neurocrine Biosciences NBIX Stock Holding History

Virtu Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Sell
1,861
-7,709
-81% -$1.14M 0.01% 714
2026
Q1 		$1.26M Sell
9,570
-5,819
-38% -$772K 0.05% 249
2025
Q4 		$2.18M Buy
15,389
+13,632
+776% +$1.97M 0.08% 146
2025
Q3 		$247K Buy
+1,757
New +$238K 0.01% 830
2024
Q4 		– Sell
-17,230
Closed -$1.99M – 1870
2024
Q3 		$1.99M Buy
+17,230
New +$2.36M 0.11% 143
2024
Q2 		– Sell
-4,212
Closed -$581K – 1689
2024
Q1 		$581K Buy
+4,212
New +$575K 0.04% 380
2023
Q3 		– Sell
-5,353
Closed -$505K – 1671
2023
Q2 		$505K Buy
+5,353
New +$523K 0.04% 397
2021
Q3 		– Sell
-6,410
Closed -$624K – 1799
2021
Q2 		$624K Buy
6,410
+1,895
+42% +$182K 0.06% 379
2021
Q1 		$439K Sell
4,515
-1,527
-25% -$160K 0.03% 586
2020
Q4 		$579K Sell
6,042
-13,877
-70% -$1.34M 0.06% 395
2020
Q3 		$1.92M Buy
19,919
+13,655
+218% +$1.58M 0.33% 48
2020
Q2 		$764K Buy
+6,264
New +$692K 0.09% 252
2019
Q4 		– Sell
-4,695
Closed -$423K – 1703
2019
Q3 		$423K Buy
+4,695
New +$439K 0.03% 581
2019
Q2 		– Sell
-9,211
Closed -$812K – 1712
2019
Q1 		$812K Buy
+9,211
New +$770K 0.05% 375
2018
Q4 		– Sell
-4,114
Closed -$506K – 1840
2018
Q3 		$506K Sell
4,114
-3,177
-44% -$360K 0.03% 599
2018
Q2 		$716K Sell
7,291
-8,450
-54% -$756K 0.04% 591
2018
Q1 		$1.3M Buy
+15,741
New +$1.33M 0.07% 275

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial's NBIX Position: Q2 2026 in Review

Virtu Financial reduced its Neurocrine Biosciences (NBIX) stake by 81% in Q2 2026, selling an estimated $1.14M and leaving 1,861 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #714.

Virtu Financial first reported a position in NBIX in Q1 2018 and has held it in 17 quarters since. The position peaked at $2.18M in Q4 2025. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Virtu Financial held 1,861 shares of Neurocrine Biosciences worth $314K as of Q2 2026.
  • Virtu Financial sold 7,709 Neurocrine Biosciences shares in Q2 2026, an estimated $1.14M.
  • Neurocrine Biosciences made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #714 holding.
  • Virtu Financial first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 17 quarters since.
  • Virtu Financial's Neurocrine Biosciences position peaked at $2.18M in Q4 2025.
  • 780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.